peptidex.
Exenatide — GLP-1 receptor agonist. No sequence or residue count is listed in the dataset. Molecular weight not listed.
GLP-1 Family

Exenatide

GLP-1 receptor agonist

A GLP-1 receptor agonist studied in type 2 diabetes, including comparisons of immediate- and extended-release formulations.

Compare compound

Also referenced as: Exendin-4

Compiled by PeptiDexProfile review date 1 linked referenceHow to read the evidence ↗
For research and educational purposes only. This page is a factual research reference, not medical advice. Any dosing figures shown are amounts reported in the research literature, provided for educational context — not instructions or recommendations for human use.

Overview

The DURATION-1 trial compared two exenatide formulations over 30 weeks in 295 adults with type 2 diabetes. This entry adds a formulation-focused comparator to the GLP-1 library.

At a glance

ClassGLP-1 receptor agonist
CategoryGLP-1 Family
AliasesExendin-4
Page purposeResearch and educational reference
Regulatory statusThis page summarizes the cited research. Regulatory authorization is specific to a product, indication and jurisdiction; consult the relevant regulator for current labeling.

Selected evidence, in context

A closer reading of selected linked publications. This is not a systematic review, an evidence grade or a complete account of safety and effectiveness.

Randomized, open-label, noninferiority trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Population or model
295 adults with type 2 diabetes; 30 weeks
Research question
How did long-acting and immediate-release exenatide formulations compare for glycemic control?
Reported finding
HbA1c fell by 1.9 percentage points in the long-acting group and 1.5 in the immediate-release group. Weight reductions were similar.
What this cannot establish
The trial was open-label and compared specific formulations of the same medicine. It does not establish equivalence with uncharacterized research material or outcomes beyond 30 weeks.

Reading note checked 2026-09-20 · PMID 18782641 · citation and indexing details

Mechanism of action

Its GLP-1 receptor activity provides the mechanistic context for studies of glucose regulation.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which Exenatide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Type 2 diabetesFormulation comparisons

Key characteristics

  • A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.

How it compares

A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.

Commonly studied alongside

Compounds frequently researched together with Exenatide in the literature. Cross-referenced for research context — not a usage or combination recommendation.

SemaglutideResearch comparator, not a combination recommendation.LiraglutideResearch comparator, not a combination recommendation.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for Exenatide, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Exenatide vs LiraglutideGLP-1 FamilyExenatide vs LixisenatideGLP-1 FamilyExenatide vs SemaglutideGLP-1 Family

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

  • Avoid repeated freeze-thaw cycles
  • Verify supplier lot and Certificate of Analysis
  • Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

Exenatide sits in the GLP-1 Family area of the PeptiDex library.

Research reference

No supplier listing is attached to this profile. The cited study describes its own formulation and population.

Read the evidence guide →

Frequently asked questions

What is the evidence context for Exenatide?

A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.

Does this reference establish that a supplier product is equivalent?

No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

Publications indexed in PubMed and linked to this profile, including original studies and reviews. Publication labels reflect PubMed indexing, not evidence strength. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).

  1. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet, 2008. PubMed 18782641

    Randomized controlled trial · Citation and indexing details

Bibliographic metadata refreshed from PubMed on 2026-09-20. This checks the record identity and metadata; it is not a new review of every scientific claim. A reference may concern a related molecule or formulation: read its methods and the context above. See the editorial policy.

SemaglutideGLP-1 FamilyTirzepatideGLP-1 FamilyRetatrutideGLP-1 FamilyLiraglutideGLP-1 Family

Further reading